Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Eberswalde – page 19

1 792 clinical trials in Eberswalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Eberswalde at a glance
1 792
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 792 trials in Eberswalde

Open in trial search

Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study to evaluate the efficacy and safety of rilzabrutinib in adults with active IgG4-related disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Potassium Chloride
  • Sponsor:Dyne Therapeutics Inc.

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

A study of daraxonrasib (RMC-6236) compared to observation in patients with resected pancreatic cancer following chemotherapy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Novartis Pharma AG

A study to evaluate the effectiveness and safety of AZD1163 in adults with moderate to severe rheumatoid arthritis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD1163
  • Sponsor:AstraZeneca AB

A study of PF-08634404, ipilimumab, and axitinib in adults with advanced or metastatic kidney cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Pfizer Inc.

A study to evaluate the safety and effectiveness of NIO752 in patients with progressive supranuclear palsy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:NIO752
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Eberswalde

What the registry says about research in the country

01 Hematologic Oncology

Clinical research focusing on Diffuse Large B-Cell Lymphoma (DLBCL) and its various subtypes, evaluating innovative combination therapies for elderly patients.

  • Treatment optimization for older adults
  • B-cell lymphoma variants
  • Targeted therapy combinations

The study explores the effectiveness of combining acalabrutinib with standard lymphoma treatments to improve outcomes in patients over 60 and 80 years of age.

02 Specialized Lymphoma Research

Investigation of multiple B-cell lymphoma subtypes, including rare variants such as primary cutaneous, intravascular, and mediastinal forms.

  • Novel therapeutic approaches
  • Rare lymphoma variants
  • Treatment response assessment

Research aims to enhance progression-free survival through targeted therapeutic strategies.

03 Personalized Medicine

Advancing treatment protocols for elderly lymphoma patients with focus on reduced-intensity therapy combinations.

  • Age-adapted treatments
  • Quality of life considerations
  • Therapeutic efficacy

Studies evaluate modified treatment regimens designed specifically for older adults who cannot tolerate standard intensive therapies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.